Supply Chain was Bnb Plus’s largest product and service line in fiscal 2025, bringing in $1.15M of $2.14M (54%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratory Testing Services (Point-In-Time) | $10.40M | $7.61M | — | — | |||||
| Product Revenues | — | — | — | — | |||||
| Product | — | — | — | — | |||||
| Clinical Laboratory Services (Over-Time) | — | $3.54M | — | — | |||||
| Clinical Laboratory Testing Services (Over-Time) | $5.13M | — | — | — | |||||
| Mdx Test Kits & Supplies | $628.29K | — | — | — | |||||
| Research & Development Services (Point-In-Time) | — | — | $311.24K | $375.76K | |||||
| Research & Development Services (Over-Time) | $592.00K | $421.59K | — | — | |||||
| Service Revenues | — | — | — | — | |||||
| Service | — | — | — | — | |||||
| Supply Chain | $887.06K | $827.60K | $1.21M | $1.15M | |||||
| Large Scale Dna Production | — | $653.02K | $584.12K | $612.36K | |||||
| Asset Marking | $534.59K | $311.81K | $9.44K | — | |||||
| Clinical Laboratory Service Revenues | — | — | — | — | |||||
| Total | $18.17M | $13.37M | $2.11M | $2.14M |
Bnb Plus brought in $2.14M from its three product and service lines in fiscal 2025, the year ended September 30, 2025. Bnb Plus regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $2.11M. Supply Chain was the largest at $1.15M (53.8%), ahead of Large Scale Dna Production at $612.36K (28.7%) and Research & Development Services (Point-In-Time) at $375.76K (17.6%).
Compared with fiscal 2024, Research & Development Services (Point-In-Time) grew fastest, up 20.7% to $375.76K, while Supply Chain fell the most, down 5.0% to $1.15M.
Bnb Plus began breaking out Research & Development Services (Point-In-Time) in fiscal 2024, when it brought in $311.24K. Bnb Plus stopped reporting Clinical Laboratory Testing Services (Point-In-Time) ($7.61M in fiscal 2023), Clinical Laboratory Testing Services (Over-Time) ($5.13M in fiscal 2022), Clinical Laboratory Services (Over-Time) ($3.54M in fiscal 2023) and three others as separate lines.
Asia & Other was Bnb Plus’s largest region in fiscal 2025, bringing in $1.02M of $2.14M (48%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $17.54M | $12.22M | $951.90K | $1.01M | |||||||
| United States | — | — | — | — | |||||||
| Us | — | — | — | — | |||||||
| Europe | $448.85K | $258.36K | $172.37K | $105.58K | |||||||
| Asia & Other | $175.39K | $886.44K | $989.23K | $1.02M | |||||||
| Total | $18.17M | $13.37M | $2.11M | $2.14M |
Bnb Plus brought in $2.14M from its three regions in fiscal 2025, the year ended September 30, 2025. That was up 1.1% from $2.11M in fiscal 2024. Asia & Other was the largest at $1.02M (47.8%), ahead of Americas at $1.01M (47.3%) and Europe at $105.58K (4.9%).
Compared with fiscal 2024, Americas grew fastest, up 6.2% to $1.01M, while Europe fell the most, down 38.7% to $105.58K. From fiscal 2022 to 2025, combined revenue from these regions fell from $18.17M to $2.14M, a compound annual decline of 51.0%. Asia & Other's share of the total rose from 1.0% to 47.8%.
Dna Tagging & Security Products was Bnb Plus’s largest segment in fiscal 2025, bringing in $1.15M of $2.14M (54%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Mdx Testing Services | $16.61M | $11.25M | $1.32M | — | |
| Dna Tagging & Security Products | $1.57M | $1.15M | $1.22M | $1.15M | |
| Therapeutic Dna Production | $439.36K | $1.07M | $895.35K | $988.12K | |
| Less Intersegment Revenues | -$452.90K | -$100.92K | — | — | |
| Total | $18.17M | $13.37M | $3.43M | $2.14M |
Bnb Plus brought in $2.14M from its two segments in fiscal 2025, the year ended September 30, 2025. Bnb Plus regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $3.43M. Dna Tagging & Security Products was the largest at $1.15M (53.8%), ahead of Therapeutic Dna Production at $988.12K (46.2%).
Compared with fiscal 2024, Therapeutic Dna Production grew 10.4% to $988.12K, while Dna Tagging & Security Products fell 5.7% to $1.15M.
Bnb Plus stopped reporting Mdx Testing Services as a separate segment after fiscal 2024, when it brought in $1.32M.
Bnb Plus (BNBX) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Supply Chain was its largest product and service line, bringing in $1.15M (53.8% of the total), followed by Large Scale Dna Production at $612.36K (28.7%).
Supply Chain was Bnb Plus' largest product and service line in fiscal 2025, bringing in $1.15M, or 53.8% of the $2.14M total across its three product and service lines.
Asia & Other was Bnb Plus' largest region in fiscal 2025, bringing in $1.02M, or 47.8% of the $2.14M total across its three regions.
Dna Tagging & Security Products was Bnb Plus' largest segment in fiscal 2025, bringing in $1.15M, or 53.8% of the $2.14M total across its two segments.
Among Bnb Plus' regions that make up at least 2% of revenue, Americas grew fastest in fiscal 2025, up 6.2% from $951.90K to $1.01M.
Every figure comes from Bnb Plus' annual financial filings, as reported. Each line keeps the name Bnb Plus gives it, and years follow its fiscal calendar.
Bnb Plus' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.